- Home
- CGEN vs NVX Comparison
CGEN vs NVX Comparison
Compare CGEN & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- NVX
- Stock Information
- Founded
- CGEN 1993
- NVX 2012
- Country
- CGEN Israel
- NVX Australia
- Employees
- CGEN N/A
- NVX N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- NVX Industrial Machinery/Components
- Sector
- CGEN Health Care
- NVX Miscellaneous
- Exchange
- CGEN Nasdaq
- NVX Nasdaq
- Market Cap
- CGEN 167.4M
- NVX 169.3M
- IPO Year
- CGEN 2000
- NVX N/A
- Fundamental
- Price
- CGEN $1.64
- NVX $1.06
- Analyst Decision
- CGEN
- NVX
- Analyst Count
- CGEN 0
- NVX 0
- Target Price
- CGEN N/A
- NVX N/A
- AVG Volume (30 Days)
- CGEN 264.8K
- NVX 89.4K
- Earning Date
- CGEN 08-05-2025
- NVX 01-01-0001
- Dividend Yield
- CGEN N/A
- NVX N/A
- EPS Growth
- CGEN N/A
- NVX N/A
- EPS
- CGEN N/A
- NVX N/A
- Revenue
- CGEN $27,589,000.00
- NVX $5,854,424.00
- Revenue This Year
- CGEN N/A
- NVX $66.66
- Revenue Next Year
- CGEN $173.80
- NVX $2,366.64
- P/E Ratio
- CGEN N/A
- NVX N/A
- Revenue Growth
- CGEN N/A
- NVX N/A
- 52 Week Low
- CGEN $1.13
- NVX $0.81
- 52 Week High
- CGEN $2.66
- NVX $2.73
- Technical
- Relative Strength Index (RSI)
- CGEN 54.29
- NVX 40.63
- Support Level
- CGEN $1.65
- NVX $1.10
- Resistance Level
- CGEN $1.83
- NVX $1.19
- Average True Range (ATR)
- CGEN 0.10
- NVX 0.06
- MACD
- CGEN -0.01
- NVX -0.01
- Stochastic Oscillator
- CGEN 47.50
- NVX 0.00
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.